Maven Securities LTD Takes $1.38 Million Position in Kyverna Therapeutics, Inc. $KYTX

Maven Securities LTD acquired a new stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 146,400 shares of the company’s stock, valued at approximately $1,376,000. Maven Securities LTD owned 0.33% of Kyverna Therapeutics at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of KYTX. Bank of America Corp DE grew its position in shares of Kyverna Therapeutics by 41.6% during the 4th quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock valued at $81,000 after acquiring an additional 6,400 shares during the period. Cubist Systematic Strategies LLC grew its position in shares of Kyverna Therapeutics by 31.1% during the 1st quarter. Cubist Systematic Strategies LLC now owns 68,628 shares of the company’s stock valued at $132,000 after acquiring an additional 16,267 shares during the period. AQR Capital Management LLC bought a new stake in shares of Kyverna Therapeutics during the 1st quarter valued at $137,000. Rhumbline Advisers grew its position in shares of Kyverna Therapeutics by 22.0% during the 1st quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock valued at $61,000 after acquiring an additional 5,694 shares during the period. Finally, XTX Topco Ltd bought a new stake in shares of Kyverna Therapeutics during the 2nd quarter valued at $107,000. Institutional investors own 18.08% of the company’s stock.

Wall Street Analysts Forecast Growth

KYTX has been the subject of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Friday, March 27th. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of Kyverna Therapeutics in a research report on Wednesday, June 3rd. Wall Street Zen downgraded shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research report on Wednesday, May 13th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $30.00.

Kyverna Therapeutics Stock Performance

Shares of Kyverna Therapeutics stock opened at $8.06 on Monday. The company has a market capitalization of $489.97 million, a P/E ratio of -2.46 and a beta of 1.96. The company has a debt-to-equity ratio of 0.13, a quick ratio of 8.15 and a current ratio of 8.15. The company has a fifty day moving average of $8.99 and a 200 day moving average of $8.55. Kyverna Therapeutics, Inc. has a fifty-two week low of $2.52 and a fifty-two week high of $13.67.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its earnings results on Tuesday, May 12th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.09. On average, sell-side analysts anticipate that Kyverna Therapeutics, Inc. will post -2.78 earnings per share for the current fiscal year.

Kyverna Therapeutics Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.